Real-World Deployment of an Ethical AI-Assisted Tele-Ultrasound Platform for Endometriosis Diagnosis in the Brazilian Public Health System: The EndoConnect Alpha Case Study and Its Evolution into the NAM-Endora Framework (Preprint)
preprint
OA: gold
CC0
Abstract
BACKGROUND Endometriosis affects 10 % of reproductive-age women globally, with diagnostic delays of 7–10 years in Brazil’s SUS. Digital platforms offer promise, but few are ethically designed with AI for low-resource settings. OBJECTIVE To report real-world deployment of EndoConnect Alpha in SUS primary care, evaluate usability/acceptability, and describe its evolution into the NAM-Endora ethical AI framework. METHODS Applied methodological study. EndoConnect Alpha (React.js + Firebase) deployed in 10 SUS units (Ceará). n = 60 (45 patients, 15 professionals). Instruments: SUS, TAM, engagement metrics, clinical-psychosocial outcomes. Ethics CAAE 82094924.8.0000.5049. INPI BR5120250005556-0. RESULTS SUS 88.9 ± 9.8 (excellent); TAM 91.4.57/5. Trail completion 79 %. Pain reduction 23 % (VAS p=0.02), therapy adherence +17 %, anxiety −14 %. Strong SUS-TAM correlation (ρ=0.76, p<0.001). CONCLUSIONS EndoConnect Alpha is feasible and impactful in SUS. NAM-Endora provides scalable ethical AI governance for LMICs. Multicenter validation planned. CLINICALTRIAL Not applicable (formative research)
Full text
2,390 characters
· extracted from
oa-html
· 5 sections
· click to expand
Abstract
Background:
Endometriosis affects 10 % of reproductive-age women globally, with diagnostic delays of 7–10 years in Brazil’s SUS. Digital platforms offer promise, but few are ethically designed with AI for low-resource settings.
Objective
To report real-world deployment of EndoConnect Alpha in SUS primary care, evaluate usability/acceptability, and describe its evolution into the NAM-Endora ethical AI framework.
Methods
Applied methodological study. EndoConnect Alpha (React.js + Firebase) deployed in 10 SUS units (Ceará). n = 60 (45 patients, 15 professionals). Instruments: SUS, TAM, engagement metrics, clinical-psychosocial outcomes. Ethics CAAE 82094924.8.0000.5049. INPI BR5120250005556-0.
Results
SUS 88.9 ± 9.8 (excellent); TAM 91.4.57/5. Trail completion 79 %. Pain reduction 23 % (VAS p=0.02), therapy adherence +17 %, anxiety −14 %. Strong SUS-TAM correlation (ρ=0.76, p<0.001).
Conclusions
EndoConnect Alpha is feasible and impactful in SUS. NAM-Endora provides scalable ethical AI governance for LMICs. Multicenter validation planned. Clinical Trial: Not applicable (formative research)
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Ask this paper
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Outcome instruments
Condition tags
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
Source provenance
- openalex
- last seen: 2026-08-03T06:04:05.111620+00:00
License: CC0
· commercial use OK